BlossomHill Therapeutics (BLSM) Stock Price

Live BlossomHill Therapeutics Stock Price, Historical BLSM Stock Price Chart

24H Range
 
 
 
52W Range
 
 
 
Last Price $ 14.02
Open $ 15.23
Previous Close $ 14.84
Volume $ 3.12M
ATH $ 28.00 (-49.93%)
ExchangeNASDAQ
P/E Ratio (TTM) -1.28
EPS (TTM) -$ 10.94
Annual Dividend (Yield) -
Market Cap $ 407.72M
BlossomHill Therapeutics Performance
Prev. Close 7 Days 1 Month 3 Months 6 Months 1 Year YTD 5 Year Max
-5.53% -3.04% 0.57% -14.41% -12.38% -12.38% -12.38% -12.38% -12.38%

About BlossomHill Therapeutics

Statistics

The BlossomHill Therapeutics stock price is currently $ 14.02 with a total market cap valuation of $ 407.72M (29.08M shares outstanding). The BlossomHill Therapeutics is trading on NASDAQ under the ticker sign BLSM. BlossomHill Therapeutics price is up -5.53% in the past 24 hours. The BlossomHill Therapeutics stock price prediction is currently bullish.

Description

Company Profile

News

BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC
BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference
BlossomHill Therapeutics: A Deliberate Beachhead Trading Back At Its IPO Price
BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

BLSM
BlossomHill Therapeutics
$ 14.02
-3.04%   Last 7D
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Updated 2 days ago